ReviewZeitschrift fur medizinische Physik2026
State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.
Review in Zeitschrift fur medizinische Physik, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organ and tumor dosimetry of [European journal of nuclear medicine and molecular imaging · 2026Article
- From photons and their detectors, ultra short and "longer" times to tiny and giant PETs, golden eyes, AI and surgical probes - Nuclear Medicine has it all.Zeitschrift fur medizinische Physik · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioligand therapy targeting the prostate-specific membrane antigen (PSMA) or somatostatin receptors (sstr) has become an established treatment option for metastatic castration-resistant prostate cancer and advanced or inoperable neuroendocrine tumours, respectively. Although several studies have already demonstrated the clinical usefulness of dosimetry-guided personalized treatment schedules, and although there is growing evidence for absorbed-dose-effect-relationships, the clinical implementation of personalized dosimetry is slow due to various factors, such as logistical constraints, a lack of standardisation or missing reimbursement. This review highlights current and future developments in quantitative imaging and personalized dosimetry for radioligand therapy. Current challenges, such as improving the accuracy and efficiency of quantitative imaging, imaging of alpha emitters, single-time-point dosimetry and PET-based absorbed dose prediction, microdosimetry and radiobiology, will be considered. Further, this review will address current ideas on how to implement dosimetry-guided treatment planning for radioligand therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.